Want to see DNA full AI Analyst Report?
DNA Stock Chart & Stats
$7.36
$0.09(1.22%)
At close: 4:00 PM EDT
$7.36
$0.09(1.22%)
Day’s Range― - ―
52-Week Range$5.37 - $17.58
Previous Close$7.4
Volume576.45K
Average Volume (3M)1.03M
Market Cap
$528.48M
Enterprise Value$395.48
Total Cash (Recent Filing)$373.46M
Total Debt (Recent Filing)$410.70M
Price to Earnings (P/E)―
Beta3.07
Next Earnings
Aug 06, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.37
Shares Outstanding53,361,140
10 Day Avg. Volume808,738
30 Day Avg. Volume1,025,627
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside63.04% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$100.55M
Bulls Say, Bears Say
Bulls Say
Diversified Platform + Downstream Value ParticipationA dual revenue model (service fees from a foundry plus royalties/equity-like downstream participation) creates durable optionality: near-term fee revenue funds operations while success-linked economics provide high-margin upside if partner products commercialize, aligning incentives long term.
Scaling Autonomous Lab (Nebula) CapacityRapid rack expansion and broad device/protocol integration build a structural capability advantage: scale increases throughput, lowers marginal cost per experiment, deepens customer lock-in via protocol libraries and integrations, and supports recurring service demand over months to years.
Strong Cash Buffer And Financing OptionalityA sizeable cash position with no bank debt materially reduces near-term refinancing risk and gives management flexibility to fund Nebula scale-up, absorb execution hiccups, and pursue strategic partnerships or spin-offs without immediate external capital dependence.
Bears Say
Sustained Revenue ContractionA multi-period revenue decline erodes operating leverage and impairs progress toward self-sustaining margins. Persistent top-line weakness reduces visibility on demand for foundry services and delays realization of downstream royalties, making profitability and growth targets harder to achieve over the medium term.
High Cash Burn And Deeply Negative MarginsLarge negative operating and free cash flows combined with very negative net margins mean the company remains reliant on external funding. Even with cost cuts, sustained burn limits strategic optionality, pressures balance sheet health, and increases execution risk if revenue recovery lags.
Operational Scaling Complexity Of NebulaComplex hardware-software integrations and scheduler issues are structural scaling risks: they can slow commercialization, raise recurring engineering and support costs, increase time-to-revenue per rack, and create customer friction that undermines long-term gross margin realization and adoption pace.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings, Inc.’s price range in the past 12 months?
Ginkgo Bioworks Holdings, Inc. lowest stock price was $5.37 and its highest was $17.58 in the past 12 months.
What is Ginkgo Bioworks Holdings, Inc.’s market cap?
Ginkgo Bioworks Holdings, Inc.’s market cap is $528.48M.
When is Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date?
Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 5 days.
How were Ginkgo Bioworks Holdings, Inc.’s earnings last quarter?
Ginkgo Bioworks Holdings, Inc. released its earnings results on May 07, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.211 by -$0.179.
Is Ginkgo Bioworks Holdings, Inc. overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings, Inc.’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings, Inc. pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
What is Ginkgo Bioworks Holdings, Inc.’s EPS estimate?
Ginkgo Bioworks Holdings, Inc.’s EPS estimate is -0.9.
How many shares outstanding does Ginkgo Bioworks Holdings, Inc. have?
Ginkgo Bioworks Holdings, Inc. has 53,361,140 shares outstanding.
What happened to Ginkgo Bioworks Holdings, Inc.’s price movement after its last earnings report?
Ginkgo Bioworks Holdings, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.211. Following the earnings report the stock price went down -13.469%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings, Inc.?
Currently, no hedge funds are holding shares in DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (63.04% Upside)
$12.00 (63.04% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 201.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: meaningful operational and strategic progress in autonomous labs (Nebula), AI-driven experiments, partnerships and a strong cash position, alongside significant near-term financial challenges including a sharp revenue decline, ongoing losses, negative adjusted EBITDA and cash costs from excess leases and one-time payments. Execution and commercialization of Nebula, cloud lab and channel partnerships will determine whether the recent technical and commercial wins translate into durable revenue growth.View all DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$12.00
▲(63.04% Upside)
Technical Analysis
Niagen Bioscience
―
Monopar Therapeutics Inc
―
Lyell Immunopharma
―
Jade Biosciences
―
AbSci
―
Ownership Overview
2.94% Insiders
15.87% Mutual Funds
6.74% Other Institutional Investors
58.84% Public Companies and Individual Investors